Related Experiment Video
Updated: Sep 6, 2025

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
A Case of Delayed Hepatic Injury Associated with Teriflunomide Use as Assessed for Causality Using the Updated RUCAM
1Department of Internal Medicine, University of New Mexico Hospital, UNM School of Medicine MSC08 47201, University of New Mexico, Albuquerque, NM 87131, USA.
Abstract:
Teriflunomide is a pyrimidine synthesis inhibitor used in the treatment of multiple sclerosis that has in rare instances been associated with liver toxicity, though there are few documented cases. Here, we report a case of probable teriflunomide-induced liver injury as assessed for causality using the updated RUCAM. The liver injury occurred approximately nine months after teriflunomide initiation and improved with discontinuation of the drug and treatment with cholestyramine.
Insights
Teriflunomide, a multiple sclerosis drug, can cause rare liver injury. This case highlights probable drug-induced liver injury, which improved after stopping teriflunomide and using cholestyramine.
Area of Science:
- Pharmacology
- Hepatology
- Neurology
Background:
- Teriflunomide is a pyrimidine synthesis inhibitor.
- It is used to treat multiple sclerosis (MS).
- Rare instances of liver toxicity have been associated with teriflunomide.
Related Concept Videos
Teratogenicity
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Hepatic Drug Excretion: Influencing Factors
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

